Related Experiment Video

Updated: May 22, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Nanobody-engineered CLL-1 CAR T cells: A strategy for safer targeting in acute myeloid leukemia

Chakrapani Tripathi1, Frank Luh1, Yun Yen1

  • 1Sino-American Cancer Foundation, Covina, CA 91722, USA.

Molecular Therapy. Oncology
|May 21, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Related Experiment Videos

Last Updated: May 22, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Association Between Body Mass Index and Overall Survival in Patients With Colorectal Cancer in Taiwan.

Anticancer research·2026

Photobiomodulation and extracellular vesicles-loaded alginate from adipose mesenchymal stem cells for cartilage repair in a rat model of osteoarthritis.

International journal of biological macromolecules·2026

Ethnic Disparities in Glioblastoma Markers: Impact of Chromosome 7 Gain and 10 Loss Alterations on Clinical Survival Outcomes.

Oncology research·2026

Source-Specific Photobiomodulation Regulates Mitochondrial Bioenergetics, Redox Signaling, and Functional Outputs in C2C12 Myoblasts Across Replicative Aging.

International journal of molecular sciences·2026

Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity.

Cancer research communications·2026

Exosomal long noncoding RNAs and microRNAs in colorectal cancer.

Tzu chi medical journal·2025

Therapeutic targeting of cancer-associated fibroblasts with oncolytic virus in preclinical models of intrahepatic cholangiocarcinoma.

Molecular therapy. Oncology·2026

Short-chain fatty acids act as metabolic and epigenetic regulators in CAR T cell therapy.

Molecular therapy. Oncology·2026

Ultrasound controllable and antigen-independent killing via cis-activating CAR T cells.

Molecular therapy. Oncology·2026

StagX1, an isoquinolinone compound, selectively targets CES1-positive Ewing sarcoma cells as a potential therapeutic agent.

Molecular therapy. Oncology·2026

Additive effect of Ruta graveolens bioactive phytoconstituents and cisplatin through PKC/MEK/ERK pathway in glioblastoma.

Molecular therapy. Oncology·2026

Erratum: Targeting AATF reprograms the tumor microenvironment and suppresses hepatocellular carcinoma via MIR100HG-TGF-β signaling.

Molecular therapy. Oncology·2026

4D nucleome landscape reveals dissolution of bipartite active X chromosome in liver cancer development.

Nature cell biology·2026

Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity.

Blood cancer journal·2026

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany-A Multi-Center Analysis.

European journal of haematology·2026

Transcription elongation by RNA polymerase II: from regulatory complexity to disease.

Trends in cell biology·2026

Modulation of X-irradiation-induced γ-H2AX focus stability in human blood lymphocytes: A technical note.

Mutation research. Genetic toxicology and environmental mutagenesis·2026

Effect of Prior Hilar Manipulation During Previous Hepatectomy on Surgical Outcomes of Laparoscopic Repeat Hepatectomy.

Asian journal of endoscopic surgery·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us